Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | GOT1 | P17174 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | MPO | P05164 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.57 |
| ▸ | ACOX1 | Q15067 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29560277 | 1.00 | KDM4E (0.57) | KDM4ETP53CYP3A4GOT1SMN1; SMN2 | |
| Formic Acid SCHEMBL30493146 | 0.89 | KDM4E (0.47) | KDM4ETP53CYP3A4GOT1SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL29015415 | 0.83 | C1S (0.62) | KDM4ETP53CYP3A4GOT1SMN1; SMN2 | |
| SCHEMBL1673296 | 0.76 | KDM4E (0.55) | KDM4ETP53CYP3A4GOT1SMN1; SMN2 | |
| SCHEMBL30523852 | 0.76 | KDM4E (0.55) | KDM4ETP53CYP3A4GOT1SMN1; SMN2 | |
| SCHEMBL30493103 | 0.76 | MEN1 (0.41) | KDM4ETP53CYP3A4GOT1SMN1; SMN2 | |
| SCHEMBL17295055 | 0.74 | NPC1 (0.53) | KDM4ETP53CYP3A4GOT1SMN1; SMN2 | |
| SCHEMBL29559673 | 0.74 | LMNA (0.47) | KDM4ECYP3A4LMNAALDH1A1CYP1A2 | |
| SCHEMBL29560021 | 0.74 | KDM4E (0.43) | KDM4ETP53CYP3A4GOT1SMN1; SMN2 | |
| SCHEMBL18630480 | 0.73 | KDM4E (0.52) | KDM4ETP53CYP3A4GOT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 642 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285947-A | Low-temperature curing polyimide precursor solution and preparation method thereof | 北京化工大学常州先进材料研究院 | 2025-01-10 | — | — | CN | claimed |
| US-20240158396-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2024-05-16 | — | — | US | claimed |
| CN-113559264-A | Methods of treating microbial infections including mastitis | 罗达制药公司 | 2021-10-29 | — | — | CN | claimed |
| CN-113144197-A | Method of treating topical microbial infections | 罗达制药公司 | 2021-07-23 | — | — | CN | claimed |
| CN-106659765-A | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer | 德玛医药 | 2017-05-10 | — | — | CN | claimed |
| EP-2137177-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2009-12-30 | — | — | EP | claimed |
| CN-100536839-C | Urea derivatives as integrin alpha 4 antagonists | ALMIRALL PRODESFARMA SA (ES) | 2009-09-09 | — | — | CN | claimed |
| EP-1984353-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2008-10-29 | — | — | EP | claimed |
| WO-2008124083-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2008-10-16 | — | — | WO | claimed |
| CN-101077865-A | Phthalazines derivatives, preparation method thereof, medicament composition and use | INST MATERIA MEDICA CAMS (CN) | 2007-11-28 | — | — | CN | claimed |
| US-20010036945-A1 | Certain Isoquinolinamine and phthalazinamine derivatives; corticotropin-releasing factor receptor CRF1 specific ligands | NEUROGEN CORPORATION. | 2001-11-01 | — | — | US | claimed |
| CN-1275124-A | Phthalazine derivatives and remedies for erectile dysfunction | EISAI CO LTD (JP) | 2000-11-29 | — | — | CN | claimed |
| US-6114530-A | ISOQUIOLINAMINES AND PHTHALAZINAMINES USEFUL IN TREATING STRESS RELATED DISORDERES SUCH AS POST TRAUMATIC STRESS DISORDER AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION (US) | 2000-09-05 | — | — | US | claimed |
| EP-0998946-A1 | Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-05-10 | — | — | EP | claimed |
| WO-2000009169-A1 | NON-PORPHYRIN COMPOUND FOR USE AS A DIAGNOSTICUM AND/OR PHARMACEUTICAL | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-02-24 | — | — | WO | claimed |
| EP-0946520-A1 | ISOQUINOLINAMINE AND PHTHALAZINAMINE DERIVATIVES WHICH INTERACT WITH CRF RECEPTORS | NEUROGEN CORPORATION (US) | 1999-10-06 | — | — | EP | claimed |
| CN-1225586-A | Remedy for erection failure comprising fused pyridazine compound | EISAI CO LTD (JP) | 1999-08-11 | — | — | CN | claimed |
| WO-1998027066-A1 | ISOQUINOLINAMINE AND PHTHALAZINAMINE DERIVATIVES WHICH INTERACT WITH CRF RECEPTORS | NEUROGEN CORPORATION (US) | 1998-06-25 | — | — | WO | claimed |
| US-4971957-A | ANTILIPEMIC AGENTS, ANTICHOLESTEROL AGENTS, BENZENECARBOXAMIDOPHOSPHONATES OR BENZENETHIOCARBOXAMIDOPHOSPHONATES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1990-11-20 | — | — | US | claimed |
| EP-0346511-A1 | Oxygen-containing hererocyclic compound, processes for their preparation and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-12-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158396-A1 | COMPOUNDS FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, PYCARD | KDM4E 4294/4885TP53 1053/4885CYP3A4 4080/4885 |
| US-20010036945-A1 | Certain Isoquinolinamine and phthalazinamine derivatives; corticotropin-releasing factor receptor CRF1 specific ligands | CRHR1, CRH, CRHR2 | KDM4E 4631/4885TP53 4210/4885CYP3A4 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.